BiondVax regains Nasdaq compliance

BiondVax Pharmaceuticals announces the receipt of formal notifications from the Nasdaq Stock Market that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity and minimum bid price. The Company previously reported on Sept. 30, 2022, and Nov. 2, 2022, receipt of the respective non-compliance notifications. Nasdaq indicated they have determined, based on the Company’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the Company once again complies with Listing Rule 5550(b)(1) regarding minimum $2.5 million stockholders’ equity. Similarly, Nasdaq communicated to BiondVax that since the minimum bid price has now closed over $1.00 per share for the past ten trading days, the Company once again complies with Listing Rule 5550(a)(2). Thus, Nasdaq has confirmed the Company now complies with Nasdaq Listing Rules and considers the abovementioned non-compliance matters to be closed.